Digitisation | November 03, 2023
Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
The campaign for the digital film is being amplified across various digital media platforms such as YouTube, Facebook, Instagram, Twitter, and LinkedIn
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
Subscribe To Our Newsletter & Stay Updated
